Graves' Disease News and Research

RSS

Graves’ disease, also known as toxic diffuse goiter, is the most common cause of hyperthyroidism in the United States. Hyperthyroidism is a disorder that occurs when the thyroid gland makes more thyroid hormone than the body needs.

Finding may aid in the design of potential therapies for thyroid problems

Thyroid disease affects about 12 percent of the U.S. population. While many people with thyroid disease don't even know they have it, an overactive or underactive thyroid can cause a slew of problems, including weight gain or loss, mood changes and infertility. In children, an underactive thyroid can be fatal, which is why they are tested for a deficiency at birth.

11 Jan 2016

Fetal microchimerism could be a subtle and dizzyingly complex puzzle

Parents go to great lengths to ensure the health and well-being of their developing offspring. The favor, however, may not always be returned.

29 Aug 2015

Endocrine Society selects 18 endocrinologists as winners of 2016 Laureate Awards

The Endocrine Society today announced it has chosen 18 accomplished endocrinologists as winners of the organization's prestigious 2016 Laureate Awards.

24 Jul 2015

Apitope's ATX-F8-117 granted FDA Orphan Drug Designation for treatment of haemophilia A patients

Apitope, the drug discovery and development company focused on disease-modifying treatments that reinstate immune tolerance, announced today that pre-clinical product candidate ATX-F8-117 has been granted Orphan Drug Status by the US Food and Drug Administration for the prevention or treatment of inhibitors in haemophilia A patients with inhibitors or at the risk of producing inhibitors.

9 Jun 2015

Intensive therapy needed in paediatric triiodothyronine-predominant Graves' disease

Paediatric patients with triiodothyronine-predominant Graves' disease develop severe disease that needs increased doses of antithyroid drugs, a study shows.

1 Apr 2015

Apitope's ATX-F8-117 granted orphan medicinal product designation for treatment of haemophilia A

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that the European Medicines Agency Committee for Orphan Medicinal Products has granted orphan medicinal product designation to ATX-F8-117 for the treatment of haemophilia A.

25 Nov 2014

New research findings on Graves' disease to be highlighted at ATA meeting

A unique mouse model of Graves' disease, an autoimmune disorder that causes hyperthyroidism, and new research findings that may help improve the treatment of Graves' disease will be highlighted in oral and poster presentations at the 84th Annual Meeting of the American Thyroid Association, October 29-November 2, 2014, in Coronado, California.

30 Oct 2014

Avalon Ventures, GSK jointly launch two new early-stage life science companies

Avalon Ventures today announced the launch of two new companies formed through its collaboration with GlaxoSmithKline to fund and launch up to 10 early-stage life science companies.

23 Sep 2014

Scientists make important breakthrough in fight against debilitating autoimmune diseases

Scientists have made an important breakthrough in the fight against debilitating autoimmune diseases such as multiple sclerosis by revealing how to stop cells attacking healthy body tissue.

3 Sep 2014

Ophthalmologist recommends alternative therapy for Graves' eye disease

Don Parker was facing a second surgery to treat the bulging eyes and double vision he was experiencing due to Graves' eye disease.

10 Jul 2014

Apitope starts preclinical development of ATX-GD-459 for Graves' disease treatment

Apitope, the drug discovery and development company focused on disease-modifying treatments for patients with autoimmune and allergic diseases, announced today that it has started preclinical development of its novel peptide therapy ATX-GD-459 for the treatment of Graves' disease.

19 Jun 2014

Autoimmune epilepsy diagnostics: an interview with Dr. Joseph J. Higgins, Medical Director, Neurology, Athena Diagnostics, a business of Quest Diagnostics

Epilepsy is a group of neurological disorders often characterized by seizures and cognitive impairment due to electrical disturbances in the brain.

From Quest Diagnostics 14 May 2014

Free educational event for patients with Graves' disease and thyroid eye disease

The Massachusetts Eye and Ear and the Graves' Disease & Thyroid Foundation will host a free educational event for patients living with Graves' disease and thyroid eye disease on Saturday, May 10 from 8:30 a.m. to noon at Mass. Eye and Ear's Meltzer Auditorium, 3rd floor, 243 Charles Street, Boston, Mass., 02114.

30 Apr 2014

AARDA launches autoimmune curriculum for teachers of grades three through eight

Furthering its mission of educating all Americans about autoimmunity and autoimmune disease (AD), the American Autoimmune Related Diseases Association, Inc. (AARDA) has launched the first-of-its kind autoimmune curriculum for teachers of grades three through eight.

22 Apr 2014

Apitope-led consortium awarded FP7 Health Innovation funding to develop Graves' disease vaccine

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announces that the consortium, led by Apitope, which includes GSK Vaccines, Quintiles and KWS Biotest Limited, has been awarded prestigious Framework Programme 7 Health Innovation funding by the European Commission to develop its Graves' disease therapeutic vaccine, including a Phase I first-in-man study in Graves' disease patients.

8 Jan 2014

Thyroid specialists recommend thyroid function testing for pregnant women

Decreased thyroid function can have a detrimental effect on pregnancy outcomes. A majority of thyroid specialists surveyed recommend thyroid function testing for all pregnant women. The results of a survey conducted at the 2012 annual meeting of the American Thyroid Association will be delivered in a poster to be presented at the upcoming 83rd Annual Meeting of the ATA, October 16-20, 2013, in San Juan, Puerto Rico.

17 Oct 2013

Researchers develop first animal model simulating eye complications linked with Graves' disease

Researchers have developed the first animal model simulating the eye complications associated with the thyroid condition Graves' disease, a breakthrough that could pave the way for better treatments, according to a recent study accepted for publication in The Endocrine Society's journal Endocrinology.

3 Sep 2013

AARDA study reveals mothers antibodies may cause autism in babies

A new, large-scale study of more than 2,700 mothers of children with autism shows that about one in 10 mothers have antibodies in their bloodstream that react with proteins in the brain of their babies.

29 Aug 2013

AARDA creates new multi-media public service campaign for AD patients

In response to a recent study that found roughly one-third of prescriptions for autoimmune disease patients go unfilled and a high level of physician mistrust exists among AD patients, the American Autoimmune Related Diseases Association, Inc. has created a new multi-media public service campaign with tools designed to help patients make informed decisions about newly-prescribed therapies and treatments.

17 Apr 2013

Lithera commences LIPO-202 Phase 2b trial for reduction of subcutaneous fat

Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, announced today that the first patient has been treated with LIPO-202 (Salmeterol Xinafoate for Injection) in its 500-patient Phase 2b "RESET" trial.

12 Mar 2013